Improved Cure Rate in Children with B-cell Acute Lymphoblastic Leukaemia and Stage IV B-cell Non-Hodgkin's Lymphoma
Author Information
Author(s): A Atra, M Gerrard, R Hobson, JD lmeson, S Ashley, CR Pinkerton
Primary Institution: The Royal Marsden Hospital NHS Trust/Institute of Cancer Research
Hypothesis
Can a short, intensive multiagent chemotherapy regimen improve outcomes for children with B-ALL and B-NHL?
Conclusion
The study confirms that the UKCCSG 9003 protocol is effective, achieving a 69% survival rate in children with B-ALL and B-NHL.
Supporting Evidence
- 43 patients (69%) survived in complete remission after treatment.
- 10 patients (16%) relapsed after achieving complete remission.
- Seven patients (11%) died of treatment-related toxicity.
Takeaway
This study shows that a special treatment can help many kids with serious blood cancers get better.
Methodology
Patients were treated with a short, intensive multiagent chemotherapy regimen based on the French LMB 86 regimen.
Limitations
The study had a small sample size and a notable rate of toxic deaths.
Participant Demographics
Patients were aged 11 months to 16.5 years, with a median age of 8.4 years; 55 were boys.
Statistical Information
Confidence Interval
55-79%
Want to read the original?
Access the complete publication on the publisher's website